Showing results (31-40 of 177) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
BRCA germline mutations in Jewish patients with pancreatic adenocarcinomaCristina R Ferrone, Douglas A Levine, Laura H Tang, et al.
Breast Cancer Research and Treatment|March 27, 2017
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriersJulia Krammer, Katja Pinker-Domenig, Mark E Robson, et al.
Journal of Pathology Informatics|December 20, 2022
Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutationDavid Joon Ho, M Herman Chui, Chad M Vanderbilt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagiaMark E Robson, Emily Glogowski, Gunhild Sommer, et al.
Annals of Surgical Oncology|September 3, 2023
Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral DiseaseJennifer Q Zhang, Carlos Henrique Dos Anjos, Varadan Sevilimedu, et al.
Gynecologic Oncology|June 12, 2003
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeMartee L Hensley, Mark E Robson, Noah D Kauff, et al.
Public Health Genomics|March 20, 2020
Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier TestJada G Hamilton, Margaux Genoff Garzon, Ibrahim H Shah, et al.
Hereditary Cancer in Clinical Practice|September 27, 2021
Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept reportSuzanne C O'Neill, Jada G Hamilton, Claire C Conley, et al.
BJU International|July 16, 2011
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancerDavid J Gallagher, Angel M Cronin, Matthew I Milowsky, et al.
Pageof 18